Daly's most recent trade in Catalyst Pharmaceuticals Inc was a trade of 50,000 Options to purchase common stock done . Disclosure was reported to the exchange on Aug. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2025 | 50,000 | 2,184,753 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.24 per share. | 26 Aug 2025 | 50,000 | 249,764 (0%) | 0% | 2.2 | 112,000 | Common stock, par value $0.001 per share |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.62 per share. | 26 Aug 2025 | 22,970 | 226,794 (0%) | 0% | 20.6 | 473,641 | Common stock, par value $0.001 per share |
| Cytokinetics Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2025 | 27,450 | 27,450 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 9.05 per share. | 12 Aug 2025 | 22,000 | 10,606 (0%) | 0% | 9.1 | 199,100 | Class A Common Stock |
| CareCloud Inc | John N. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2025 | 7,500 | 76,750 (0%) | 0% | 0 | Common Stock | |
| CareCloud Inc | John N. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2025 | 7,500 | 40,000 | - | - | Restricted Stock Unit | |
| CareCloud Inc | John N. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2025 | 25,000 | 55,000 | - | - | Restricted Stock Unit | |
| CareCloud Inc | John N. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2025 | 7,500 | 69,250 (0%) | 0% | 0 | Common Stock | |
| CareCloud Inc | John N. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2025 | 7,500 | 47,500 | - | - | Restricted Stock Unit | |
| Nasdaq | Michelle Daly | SVP, Controller & PAO | Sale of securities on an exchange or to another person at price $ 93.45 per share. | 25 Jul 2025 | 8,691 | 8,879 (0%) | 0% | 93.5 | 812,174 | Common Stock, par value $0.01 per share |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 1,290 | 1,290 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 715 | 2,627 (0%) | 0% | 0 | Common Stock | |
| CareCloud Inc | John N. Daly | Director | Sale of securities on an exchange or to another person at price $ 2.11 per share. | 17 Jun 2025 | 15,000 | 61,750 (0%) | 0% | 2.1 | 31,650 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 125.55 per share. | 06 Jun 2025 | 1,977 | 24,976 (0%) | 0% | 125.5 | 248,212 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 126.39 per share. | 06 Jun 2025 | 400 | 24,576 (0%) | 0% | 126.4 | 50,556 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 128.67 per share. | 06 Jun 2025 | 3 | 24,573 (0%) | 0% | 128.7 | 386 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 127.65 per share. | 02 Jun 2025 | 6,946 | 29,381 (0%) | 0% | 127.7 | 886,657 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 122.05 per share. | 02 Jun 2025 | 5,415 | 45,577 (0%) | 0% | 122.1 | 660,901 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 123.46 per share. | 02 Jun 2025 | 5,230 | 36,327 (0%) | 0% | 123.5 | 645,696 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 122.64 per share. | 02 Jun 2025 | 4,020 | 41,557 (0%) | 0% | 122.6 | 493,013 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 128.26 per share. | 02 Jun 2025 | 2,428 | 26,953 (0%) | 0% | 128.3 | 311,415 | Common Stock |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 24.86 per share. | 30 May 2025 | 70,000 | 199,764 (0%) | 0% | 24.9 | 1,740,200 | Common stock, par value $0.001 per share |
| Acadia Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 13,793 | 13,793 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 9,387 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 9,387 | 34,041 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 8,107 | 8,107 | - | - | Restricted Stock Units | |
| SkyWater Technology Inc | Edward M. Daly | Director | Grant, award, or other acquisition of securities at price $ 8.75 per share. | 21 May 2025 | 11,428 | 34,879 | - | 8.8 | 99,995 | Common Stock |
| Olin Corp | Edward M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 9,157 | 9,157 | - | - | Phantom Stock Units | |
| Olin Corp | Edward M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 492 | 9,649 | - | - | Phantom Stock Units | |
| Nasdaq | Michelle Daly | SVP, Controller & PAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.30 per share. | 03 Apr 2025 | 424 | 17,247 (0%) | 0% | 78.3 | 33,199 | Common Stock, par value $0.01 per share |
| Nasdaq | Michelle Daly | SVP, Controller & PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 2,169 | 18,051 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Broadridge Financial | Richard J. Daly | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.72 per share. | 01 Apr 2025 | 604 | 103,489 (0%) | 0% | 244.7 | 147,811 | Common Stock |
| Nasdaq | Michelle Daly | SVP, Controller & PAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.86 per share. | 01 Apr 2025 | 380 | 17,671 (0%) | 0% | 75.9 | 28,827 | Common Stock, par value $0.01 per share |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 8.73 per share. | 05 Mar 2025 | 46,936 | 32,606 (0%) | 0% | 8.7 | 409,751 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 8.88 per share. | 05 Mar 2025 | 43,064 | 79,542 (0%) | 0% | 8.9 | 382,408 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 194,064 | 194,064 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 97,032 | 97,032 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 90,580 | 133,644 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 90,580 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 38,226 | 53,928 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 38,226 | 76,453 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 35,879 | 107,640 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 35,879 | 138,185 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 31,338 | 102,306 (0%) | 0% | 8.8 | 274,521 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 22,645 | 22,645 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 22,645 | 22,645 (0%) | 0% | - | Class A Common Stock | |
| Kimbell Royalty Partners LP | Matthew S. Daly | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.42 per share. | 03 Mar 2025 | 16,725 | 682,843 (2%) | 0% | 14.4 | 241,175 | Common units representing limited partner interests |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.84 per share. | 03 Mar 2025 | 15,579 | 122,606 (0%) | 0% | 8.8 | 137,718 | Class A Common Stock |
| Kimbell Royalty Partners LP | Matthew S. Daly | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.32 per share. | 03 Mar 2025 | 14,717 | 712,587 (2%) | 0% | 15.3 | 225,464 | Common units representing limited partner interests |
| Kimbell Royalty Partners LP | Matthew S. Daly | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.32 per share. | 03 Mar 2025 | 13,019 | 699,568 (2%) | 0% | 15.3 | 199,451 | Common units representing limited partner interests |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 10,864 | 43,064 (0%) | 0% | 8.8 | 95,169 | Class A Common Stock |
| Amneal Pharmaceuticals Inc | Jason B. Daly | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 6,943 | 15,702 (0%) | 0% | 8.8 | 60,821 | Class A Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 347.39 per share. | 27 Feb 2025 | 14,302 | 2,682 (0%) | 0% | 347.4 | 4,968,372 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 9,470 | 0 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.06 per share. | 27 Feb 2025 | 9,470 | 11,382 (0%) | 0% | 65.1 | 616,118 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 111.06 per share. | 27 Feb 2025 | 6,000 | 17,382 (0%) | 0% | 111.1 | 666,360 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 348.94 per share. | 27 Feb 2025 | 770 | 1,912 (0%) | 0% | 348.9 | 268,686 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 346.90 per share. | 27 Feb 2025 | 398 | 16,984 (0%) | 0% | 346.9 | 138,067 | Common Stock |
| Kimbell Royalty Partners LP | Matthew S. Daly | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 153,000 | 727,304 (2%) | 0% | 0 | Common units representing limited partner interests | |
| Nasdaq | Michelle Daly | Controller and Prin Acctg Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 5,514 | 17,937 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Nasdaq | Michelle Daly | Controller and Prin Acctg Ofcr | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.24 per share. | 19 Feb 2025 | 2,056 | 15,882 (0%) | 0% | 81.2 | 167,029 | Common Stock, par value $0.01 per share |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 4,000 | 271,338 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 4,000 | 2,234,753 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 14 Feb 2025 | 1,574 | 269,764 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Blackboxstocks Inc | Dalya Sulaiman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 5,000 | 8,750 | - | - | Common Stock Options | |
| CareCloud Inc | John N. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 7,500 | 30,000 | - | - | Restricted Stock Unit | |
| CareCloud Inc | John N. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 7,500 | 76,750 (0%) | 0% | 0 | Common Stock | |
| Broadridge Financial | Richard J. Daly | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 4,241 | 4,241 | - | - | Stock Option (Right to Buy) | |
| CareCloud Inc | John N. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 7,500 | 37,500 | - | - | Restricted Stock Unit | |
| CareCloud Inc | John N. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 7,500 | 69,250 (0%) | 0% | 0 | Common Stock | |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 42,105 | 277,938 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 42,105 | 2,238,753 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jan 2025 | 10,600 | 267,338 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| CareCloud Inc | John N. Daly | Director | Sale of securities on an exchange or to another person at price $ 3.87 per share. | 31 Dec 2024 | 5,000 | 61,750 (0%) | 0% | 3.9 | 19,350 | Common Stock |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 1,333 | 2,280,858 | - | - | Restricted Stock Units | |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 1,333 | 236,157 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 27 Dec 2024 | 324 | 235,833 (0%) | 0% | - | Common Stock, par value $0.001 per share | |
| CareCloud Inc | John N. Daly | Director | Sale of securities on an exchange or to another person at price $ 3.65 per share. | 02 Dec 2024 | 10,000 | 66,750 (0%) | 0% | 3.7 | 36,500 | Common Stock |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 491,160 | 2,222,172 | - | - | Options to purchase common stock | |
| Catalyst Pharmaceuticals Inc | Richard J. Daly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 60,019 | 2,282,191 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 8.40 per share. | 21 Nov 2024 | 13,665 | 0 (0%) | 0% | 8.4 | 114,786 | Class A Common Stock |
| Broadridge Financial | Richard J. Daly | Director, Executive Chairman | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Nov 2024 | 1,000 | 104,093 (0%) | 0% | 0 | Common Stock | |
| Amneal Pharmaceuticals Inc | Jason B. Daly | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 8.61 per share. | 15 Nov 2024 | 43,657 | 13,665 (0%) | 0% | 8.6 | 375,887 | Class A Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 129.62 per share. | 13 Nov 2024 | 25,727 | 56,721 (0%) | 0% | 129.6 | 3,334,734 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 128.65 per share. | 13 Nov 2024 | 13,644 | 82,448 (0%) | 0% | 128.7 | 1,755,301 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 130.43 per share. | 13 Nov 2024 | 5,729 | 50,992 (0%) | 0% | 130.4 | 747,233 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 110,619 | 166,445 (0%) | 0% | 0 | Common Stock | |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 139.14 per share. | 07 Nov 2024 | 49,061 | 117,384 (0%) | 0% | 139.1 | 6,826,348 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 134.27 per share. | 07 Nov 2024 | 9,679 | 101,567 (0%) | 0% | 134.3 | 1,299,599 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 135.25 per share. | 07 Nov 2024 | 4,775 | 96,792 (0%) | 0% | 135.3 | 645,819 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 133.45 per share. | 07 Nov 2024 | 4,241 | 111,246 (0%) | 0% | 133.4 | 565,961 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 137.86 per share. | 07 Nov 2024 | 1,897 | 115,487 (0%) | 0% | 137.9 | 261,520 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 136.73 per share. | 07 Nov 2024 | 700 | 96,092 (0%) | 0% | 136.7 | 95,711 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 111.81 per share. | 29 Oct 2024 | 3,456 | 59,492 (0%) | 0% | 111.8 | 386,415 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 112.77 per share. | 29 Oct 2024 | 2,817 | 56,675 (0%) | 0% | 112.8 | 317,673 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 119.33 per share. | 29 Oct 2024 | 1,583 | 63,794 (0%) | 0% | 119.3 | 188,899 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 120.04 per share. | 29 Oct 2024 | 846 | 62,948 (0%) | 0% | 120.0 | 101,554 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 114.25 per share. | 29 Oct 2024 | 649 | 56,026 (0%) | 0% | 114.2 | 74,148 | Common Stock |
| MACOM Technology Solutions | Stephen G. Daly | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 117.55 per share. | 29 Oct 2024 | 200 | 65,377 (0%) | 0% | 117.6 | 23,510 | Common Stock |